A Multi-centre Phase 2 Study of Azacitidine in Chronic Myelomonocytic Leukaemia

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2014 Feb 27

PMID 24569776

Citations 19

Authors

M W Drummond

C Pocock

M Boissinot

J Mills

J Brown

P Cauchy

N C P Cross

S Hartley

J Kell

A Szubert

P N Cockerill

D T Bowen

Affiliations

Soon will be listed here.

Citing Articles

Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms.

Gerke M, Christodoulou I, Karantanos T Cancers (Basel). 2023; 15(15).

PMID: 37568631 PMC: 10417399. DOI: 10.3390/cancers15153815.

Role and mechanism of DNA methylation and its inhibitors in hepatic fibrosis.

Lyu S, Xiao W, Cui G, Yu C, Liu H, Lyu M Front Genet. 2023; 14:1124330.

PMID: 37056286 PMC: 10086238. DOI: 10.3389/fgene.2023.1124330.

Treatment Outcomes and Prognostic Factors in 66 Patients with Chronic Myelomonocytic Leukemia (CMML) in a Single Center.

Wang C, Wang Z, Meng F, Luo L, Liu X, Shi J Int J Gen Med. 2023; 15:7843-7854.

PMID: 36644378 PMC: 9835103. DOI: 10.2147/IJGM.S371766.

The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.

Moyo T, Mendler J, Itzykson R, Kishtagari A, Solary E, Seegmiller A BMC Cancer. 2022; 22(1):1013.

PMID: 36153475 PMC: 9509596. DOI: 10.1186/s12885-022-10073-w.

Real-world data on efficacy and safety of azacitidine therapy in chronic myelomonocytic leukemia in China: results from a multicenter, retrospective study.

Xu Y, Guo R, Miao M, Zhang G, Lan J, Jin J Invest New Drugs. 2022; 40(5):1117-1124.

PMID: 35834039 PMC: 9395485. DOI: 10.1007/s10637-022-01283-x.

References

Braun T, Itzykson R, Renneville A, de Renzis B, Dreyfus F, Laribi K . Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood. 2011; 118(14):3824-31. DOI: 10.1182/blood-2011-05-352039. View

Grand F, Hidalgo-Curtis C, Ernst T, Zoi K, Zoi C, McGuire C . Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood. 2009; 113(24):6182-92. DOI: 10.1182/blood-2008-12-194548. View

Kaminskas E, Farrell A, Abraham S, Baird A, Hsieh L, Lee S . Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res. 2005; 11(10):3604-8. DOI: 10.1158/1078-0432.CCR-04-2135. View

Thorpe M, Montalvao A, Pierdomenico F, Moita F, Almeida A . Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: a case series and literature review. Leuk Res. 2012; 36(8):1071-3. DOI: 10.1016/j.leukres.2012.04.024. View

Wattel E, Guerci A, Hecquet B, Economopoulos T, Copplestone A, Mahe B . A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Français des Myélodysplasies and European CMML Group. Blood. 1996; 88(7):2480-7. View

Kantarjian H, Oki Y, Garcia-Manero G, Huang X, OBrien S, Cortes J . Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2006; 109(1):52-7. DOI: 10.1182/blood-2006-05-021162. View

Ades L, Sekeres M, Wolfromm A, Teichman M, Tiu R, Itzykson R . Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. Leuk Res. 2013; 37(6):609-13. DOI: 10.1016/j.leukres.2013.01.004. View

Cheson B, Greenberg P, Bennett J, Lowenberg B, Wijermans P, Nimer S . Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006; 108(2):419-25. DOI: 10.1182/blood-2005-10-4149. View

Costa R, Abdulhaq H, Haq B, Shadduck R, Latsko J, Zenati M . Activity of azacitidine in chronic myelomonocytic leukemia. Cancer. 2011; 117(12):2690-6. DOI: 10.1002/cncr.25759. View

10.

Ernst T, Chase A, Score J, Hidalgo-Curtis C, Bryant C, Jones A . Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet. 2010; 42(8):722-6. DOI: 10.1038/ng.621. View

11.

Fenaux P, Mufti G, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A . Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009; 10(3):223-32. PMC: 4086808. DOI: 10.1016/S1470-2045(09)70003-8. View

12.

Score J, Hidalgo-Curtis C, Jones A, Winkelmann N, Skinner A, Ward D . Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. Blood. 2011; 119(5):1208-13. DOI: 10.1182/blood-2011-07-367243. View